# US 2021/0198753 A1 · Systems and methods for determining a treatment course of action

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0198753 A1
- Document ID: US20210198753A1
- Status: Published application
- Kind: A1
- Application number: 17/253,690
- Filed: 2019-06-21
- Published: 2021-07-01
- Earliest claimed: 2018-06-21
- Assignees: Arizona Board of Regents on Behalf of the University of Arizona
- Applicants: Arizona Board of Regents on Behalf of the University of Arizona
- Inventors: Ghassan Mouneimne; Marco Padilla-Rodriguez
- Web page: https://patentgrep.com/patent/US20210198753A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 31/015: carbocyclic
- A61K 31/10: Sulfides; Sulfoxides; Sulfones
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 31/5685: having an oxo group in position 17, e.g. androsterone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- G01N 2333/723: Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure relates to methods of determining a treatment course of action. In particular, the present disclosure relates to compositions and methods for determining responsiveness to estrogen and estrogen blocking therapies for cancer.

## Claims

### Claim 1

A method of treating cancer, comprising:
a) assaying a sample from a subject diagnosed with cancer for the level of expression of Enah/Vasp-Like gene (EVL) and estrogen receptor; and
b) administering anti-estrogen therapy when said sample is positive for estrogen receptor expression and level of expression of EVL is lower than a reference level and not administering anti-estrogen therapy when the level of expression of EVL is higher than said reference level.

### Claim 2 (depends on 1)

The method of claim 1, wherein said method further comprises administering an agent that increases the level of expression of EVL when said level of EVL is lower than said reference level.

### Claim 3 (depends on 1)

The method of claim 1, wherein said anti-estrogen therapy is an estrogen receptor antagonist or an aromatase inhibitor.

### Claim 4 (depends on 1)

The method of claim 1, wherein said anti-estrogen therapy is selected from the group consisting of tamoxifen, fulvestrant, toremifene, letrozole, anastrozole, and exemestane.

### Claim 5 (depends on 1)

The method of claim 1, wherein the sample is selected from the group consisting of tissue, blood, plasma, serum, and breast cells.

### Claim 6 (depends on 1)

The method of claim 1, wherein said cancer is breast cancer.

### Claim 7 (depends on 6)

The method of claim 6, wherein said breast cells are estrogen receptor positive breast cancer cells.

### Claim 8 (depends on 1)

The method of claim 1, wherein said method further comprises administering chemotherapy.

### Claim 9 (depends on 1)

The method of claim 1, wherein following administration of said anti-estrogen therapy, estrogen therapy is administered to said subject.

### Claim 10 (depends on 9)

The method of claim 9, wherein said subject does not exhibit a response to said anti-estrogen therapy.

### Claim 11 (depends on 9)

The method of claim 9, wherein said estrogen promotes the generation of Suppressive Cortical Actin Bundles (SCABs).

### Claim 12 (depends on 6)

The method of claim 6, further comprising measuring the level of fibrosis of said cancer cells.

### Claim 13 (depends on 12)

The method of claim 12, wherein subjects with high levels of fibrosis in in said cancer cells and levels of EVL above a reference level are administered anti-estrogen therapy.

### Claim 14 (depends on 12)

The method of claim 12, wherein the level of fibrosis is measured using matrix-specific staining.

### Claim 15

A method of treating cancer, comprising:
a) assaying a sample from a subject diagnosed with cancer for the level of expression of i) a tumor marker selected from the group consisting of EVL, TMSB15B, TMSB15B, MYO10, ANLN, TNNT1, ABLIM3, FMNL2, and LIMA1 and ii) estrogen receptor; and
b) administering anti-estrogen therapy when said level of expression of said tumor marker is lower than a reference level and not administering anti-estrogen therapy when the level of expression of said tumor marker is higher than said reference level.

### Claim 16

A method of treating cancer, comprising:
a) assaying a sample from a subject diagnosed with breast cancer for the level of expression of EVL; and
b) administering estrogen therapy when said level of expression of EVL is lower than a reference level.

### Claim at position 17

17-20. (canceled)

### Claim 21 (depends on 1)

The method of claim 1, wherein said reference level is the level of expression in estrogen negative breast cancer cells.
